Presence and characteristics of receptors for [D-Trp6]luteinizing hormone releasing hormone and epidermal growth factor in human ovarian cancer

International Journal of Oncology

Volumn 12, Issue 3, 1998, Pages 489-498

  Srkalovic, Gordan ^a,c   Schally, Andrew V ^a   Wittliff, James L ^b   Day Jr , Thomas G ^b   Jenison, Eric L ^c,d  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF LOUISVILLE   (United States)

^c NORTHEAST OHIO MEDICAL UNIVERSITY   (United States)

^d NONE   (United States)

Author keywords

EGF receptors; LH RH analogs; LH RH receptors; Ovarian cancer

Indexed keywords

CETRORELIX; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; GONADORELIN ANTAGONIST; GONADORELIN RECEPTOR; IODINE 125; MEMBRANE RECEPTOR; TRIPTORELIN;

ADULT; AGED; ARTICLE; BINDING KINETICS; BINDING SITE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HORMONE RECEPTOR INTERACTION; HUMAN; HUMAN TISSUE; LIGAND BINDING; OVARY CANCER; PRIORITY JOURNAL; RADIOASSAY; RECEPTOR AFFINITY;

EID: 0031908127     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.12.3.489     Document Type: Article

References (41)

1. MRC Gynecologic Cancer Working Party, Guest Editorial: An overview in the treatment of advanced ovarian cancer. Br J Cancer 61: 495-496, 1990.
2. Averette HE and Donato DM: Ovarian carcinoma, advances in diagnosis, staging and treatment. Cancer 65: 703-708, 1990.
3. Blackledge G and Lawton FG: Second Birmingham Gynaecological Cancer Workshop on Second Line Treatment of Ovarian Cancer (May 12, 1988). Br J Cancer 59: 657-659, 1989.
4. Morrow CP and Townsend DE (eds): Synopsis of gynecologic oncology. John Wiley and Sons, New York, pp270-271, 1987.
5. Kaldor JM, Day NE, Pettersson R, Clarke EA, Pedersen D, Mehnert W, Bell J, Høst H, Prior P, Karjalainen S, Neal F, Koch M, Band P, Choi W, Dompe-Kim V, Arslan A, Zarén B, Belch AR, Storm H, Kittelmann B, Fraser P and Stovall M: Leukemia following chemotherapy for ovarian cancer. N Engl J Med 322: 1-6, 1990.
6. Friberg LG, Kullander S, Persijn JP and Korsten CB: On receptors for estrogens E2 and androgens (DHT) in human endometrial carcinoma and ovarian tumours. Acta Obstet Gynecol Scand 57: 261-264, 1978.
7. Harding M, Cowan S, Hole D, Cassidy L, Kitchener H, Davis J and Leake R: Estrogen and progesterone receptors in ovarian cancer. Cancer 65: 486-491, 1990.
8. Emons G, Pahwa GS, Brack C, Sturm R, Oberheauser F and Knuppen R: Gonadotropin releasing hormone binding sites in human epithelial ovarian carcinomata. Eur J Cancer Oncol 25: 215-221, 1989.
9. 6]LHRH. Cancer Treatment Rep 69: 1341, 1989.
10. 6]LHRH (Decapeptyl) microcapsules in advanced ovarian cancer. Br Med J 296: 1229, 1988.
11. 6]LH-RH (Decapeptyl) microcapsules. Biomed Pharmacother 43: 531-538, 1988.
12. Pahwa GS, Vollmer G, Knuppen R and Emons G: Photoaffinity labelling of gonadotropin releasing hormone binding sites in human epithelial ovarian carcinoma. Biochem Biophys Res Commun 161: 1086-1092, 1989.
13. Schally AV and Comaru-Schally AM: Hypothalamic and other peptide hormones. In: Cancer Medicine. Holland JF, Frei E III, Bast RC Jr, Kufe DE, Morton DL and Weichselbaum RR (eds). 4th edition. Williams and Wilkins, Baltimore, MD, pp1067-1086, 1997.
14. Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254, 1976.
15. 131I labelled growth hormone of high specific radioactivity. Biochem J 89: 114-123, 1963.
16. 6]-luteinizing hormonereleasing hormone and epidermal growth factor in human endometrial carcinoma. Cancer Res 50: 1841-1846, 1990.
17. Munson PJ and Rodbard D: Ligand: a versatile computerized approach for characterization of ligand-binding system. Anal Biochem 107: 220-239, 1980.
18. Köves K, Gottschall PE and Arimura A: Gonadotropin-releasing hormone binding sites in ovaries of normal cycling and persistentestrus rats. Biol Reprod 41: 505-511, 1989.
19. Séguin C, Pelletier G, Dubé D and Labrie F: Distribution of luteinizing hormone-releasing hormone receptors in the rat ovary. Regul Pept 4: 183-190, 1982.
20. Bramley TA, Menzies GS and Baird DT: Specific binding of gonadotropin releasing hormone and an agonist to human corpus luteum homogenates: characterization, properties, and luteal phase levels. J Clin Endocrinol Metab 61: 834-841, 1985.
21. Clayton RN and Huhtaniemi IT: Absence of gonadotropinreleasing hormone receptors in human gonadal tissue. Nature 299: 56-59, 1982.
22. Emons G, Ortmann O, Pahwa GS, Lohrs U, Wetterling T, Dilling H, Oberhauser F and Knuppen R: In vivo- und in vitroEffekte vone GnRH-Analoga auf einen ovarieellen Leydig cell tumor. Geburtsh Frauenheilk 52: 487-493, 1992.
23. Kakar SS, Musgrove LC, Devor DC, Sellers JC and Neill JD: Cloning, sequencing, and expression of human gonadotropin releasing hormone (GnRH) receptor. Biochem Biophys Res Commun 189: 289-295, 1992.
24. Reinhart J, Mertz LM and Catt KJ: Molecular cloning and expression of cDNA encoding the murine gonadotropinereleasing hormone receptor. J Biol Chem 267: 21281-21284, 1992.
25. Emons G and Schally AV: The use of luteinizing hormone releasing hormone agonists and antagonists in gynaecological cancers. Hum Reprod 9: 1364-1379, 1994.
26. Raymoure WJ, McNaught RW, Green GL and Smith RG: Receptor interconversion model of hormone action; II. Nucleotide-mediated conversion of estrogen receptors from nonsteroid binding to the lower affinity binding state. J Biol Chem 261: 17018-17025, 1986.
27. Erickson J, Goldstein B, Holowka D and Baird B: The effect of receptor density on the forward rate constant for binding of ligands to cell surface receptors. Biophys J 52: 657-662, 1987.
28. Bauknecht T, Kiechle M, Bauer G and Siebers JW: Characterization of growth factors in human ovarian carcinomas. Cancer Res 46: 2614-2619, 1986.
29. Sherwin SA, Twardzik DR, Bohn WH, Cockley KD and Todaro GJ: High-molecular-weight transforming growth factor activity in the urine of patients with disseminated cancer. Cancer Res 43: 403-407, 1983.
30. Goustin AS, Leof EB, Shipley GD and Moses HL: Growth factors and cancer. Cancer Res 46: 1015-1029, 1986.
31. Birnbaumer L, Shahabi N, Rivier J and Vale W: Evidence for a physiologic role of gonadotropin-releasing hormone (GnRH) or GnRH-like material in the ovary. Endocrinology 116: 1367-1370, 1985.
32. 10]luteinizing hormone-releasing hormone ethylamide on developing rat ovarian follicles. Cancer Res 47: 5005-5008, 1987.
33. 6]LH-RH: a preliminary report. Cancer Lett 41: 105-110, 1988.
34. Mortel R, Sayaswaroop PG, Schally AV, Hamilton T and Ozols R: Inhibitory effect of GnRH superagonist on the growth of human ovarian carcinoma NIH: OVCAR3 in the nude mouse. Gynecol Oncol 23: 254-255, 1986.
35. Limonta P, Dondi D, Moretti RM, Maggi R and Motta M: Antiproliferative effects of luteinizing hormone-releasing hormone agonists on the human prostatic cancer cell line LNCaP. J Clin Endocrinol Metab 75: 207-212, 1992.
36. Fekete M, Redding TW, Comaru-Schally AM, Pontes JE, Connelly RW, Srkalovic G and Schally AV: Receptors for luteinizing hormone-releasing hormone, somatostatic, prolactin, and epidermal growth factor in rat and human prostate cancers and in benign prostate hyperplasia. Prostate 14: 191-208, 1989.
37. Fekete M, Zalatnai A, Comaru-Schally AM and Schally AV: Membrance receptors for peptides in experimental and human pancreatic cancers. Pancreas 4: 521-528, 1989.
38. Emons G, Ortmann O, Telchert HM, Fess H, Lohrs U, Kullander S, Kauppila A, Ayalon D, Schally A, Oberheuser F, Ude L, Stig K, Aniti K and Daniel A: Luteinizing hormonereleasing hormone agonist Triptorelin in combination with cytotoxic chemotherapy in patients with advanced ovarian carcinoma. Cancer 78: 1452-1460, 1996.
39. Bajusz S, Csernus VJ, Janaky T, Bokser L, Fekete M and Schally AV: New antagonists of LHRH: II. Inhibition and potentiation of LHRH by closely related analogues. Int J Pept Protein Res 32: 425-435, 1988.
40. Schally AV, Srkalovic G, Szende B, Redding TW, Janaky T, Juhasz A, Korkut E, Cai R-Z, Szepeshazi K, Radulovic S, Bokser L, Groot K, Serfozo P and Comaru-Schally AM: Antitumor effects of analogs of LH-RH and Somatostatin: experimental and clinical studies. J Steroid Biochem 37: 1061-1067, 1990.
41. Srkalovic G, Cai R-Z and Schally AV: Evaluation of receptors for somatostatin in various tumors using different analogs. J Clin Endocrinol Metab 70: 661-669, 1990.